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Background
Multiplexed imaging is a rapidly growing field that promises to substan-
tially increase the number of proteins that can be imaged simultaneously.
We have developed Multiplexed Ion Beam Imaging by Time of Flight
(MIBI-TOF), which uses elemental reporters conjugated to primary anti-
bodies that are then quantified using a time of flight mass-spectrometer.
This technique allows for more than 40 distinct proteins to visualized at
once in the same clinical samples. This has already yielded significant in-
sights into the interactions and relationships between the many different
immune cell populations present in the tumor microenvironment. How-
ever, one of the remaining challenges in analyzing such data is accurately
determining target protein expression values for each cell in the image.
This requires the precise delineation of boundaries between cells that are
often tightly packed next to one another. Current methods to address
this challenge largely rely on DNA intensity to make these splits, and are
thus mostly limited to nuclear segmentation.
Methods
We have developed a novel convolutional neural network to perform
whole-cell segmentation from multiplexed imaging data. Rather than
relying only on DNA signal, we use a panel of morphological
markers. Our method integrates the information from these distinct
proteins, allowing it to segment large cancer cells, small lympho-
cytes, and normal epithelium at the same time without requiring
fine-tuning or manual adjustment.
Results
By combining our novel imaging platform with new computational
tools, we are able to achieve extremely accurate segmentation of
whole cells in tissue. Our approach compares favorably with many of
the currently used tools for segmentation. We show that our improve-
ments in accuracy come both from our novel imaging approach as well
as algorithmic advances. We perform significantly better than trad-
itional machine learning algorithms trained on the same dataset. Add-
itionally, we show that our algorithm can be trained to identify cells
across a range of cancer histologies and disease grades.
Conclusions
We have developed a robust and accurate approach to whole-cell
segmentation in human tissues. We show the superiority over this
method over current state of the art algorithms. The accurate seg-
mentation generated by our approach will enable the analysis of
complex tissue architectures with highly overlapping cell types, and
will help to advance our understanding of the interactions between
cell types in the diseased state.
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Background
The objective of this model-based meta-analysis is to characterize
the exposure-response (overall response rate [ORR]) across approved
anti-PD(L)1 agents (nivolumab, pembrolizumab, atezolizumab, avelu-
mab and durvalumab) to quantify the effect of drug, patient and trial
characteristics on ORR, and assess the-relationship between ORR and
efficacy outcomes such as 6-month progression-free survival (PFS)
and 12-month overall survival (OS).
Methods
A clinical outcomes database was generated using published data
for anti-PD(L)1 agents through March 2018. Reported exposures fol-
lowing Cycle 1 were normalized by the potency of the anti-PD(L)1
agents using respective IC50 values. Exposure-response (ORR) ana-
lysis was conducted using bayesian mixed effects modeling (R soft-
ware), and included weighting by the number of subjects in each
trial arm. Tumor type, number of prior therapies, ECOG performance,
line of treatment, region, age, and gender were evaluated as model
covariates. Impact of PD-L1 expression cut-off values was assessed to
estimate the effect of PD-L1 expression on ORR. Correlation analyses
were conducted between ORR, 6-month PFS and 12-month OS.
Results
Clinical data from 56 trials in approximately 11,000 subjects, and ap-
proximately 45 trials in 9,000 subjects across approved anti-PD(L)1s
was included for the exposure-response and correlation analyses, re-
spectively. A log-transformed linear model best described the flat
exposure-response relationship, with tumor type as the most signifi-
cant covariate (p < 0.001): the predicted ORR across the agents at ap-
proved dose ranges was 22% (95% CI: 16 – 30%) in non-small cell
lung cancer. ORR appeared to increase by approximately 8 - 12%
with greater PD-L1 expression (≥5% and ≥10% cut-offs respectively).
ORR was correlated with 6-month PFS and 12-month OS (correlation
coefficient, r = 0.6-0.7), and indicated a significant effect of tumor
type on the correlation.
Conclusions
The model-based meta-analysis of exposure-response shows similar
ORR depending on tumor type, across anti-PD(L)1s at the approved
clinical doses. Improved efficacy was predicted with greater (i.e. ≥
5%) PD-L1 expression.
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Background
Tumor purity (TP) estimation is routinely performed for whole exome se-
quencing (WES) analysis to ensure signal is derived from cancer cells and
not from other cells in the tumor microenvironment. Low TP has been
shown to impact assessment of immunotherapy-related biomarkers in-
cluding tumor mutational burden (TMB) [1]. While several methodologies
exist to estimate TP by WES, a majority of studies do not compare against
pathologist estimation, the gold standard. In this study, we utilize
artificial-intelligence (AI)-based image analysis to estimate TP, and further
benchmark two methodologies of TP estimation on WES against patholo-
gist and AI estimates across 1509 pretreatment samples from patients
with melanoma, non-small cell lung cancer, small cell lung cancer, or
urothelial carcinoma enrolled in clinical trials of nivolumab.
Methods
To assess TP by WES, paired tumor-normal samples were processed
by Sentieon [2] or Strelka [3] somatic variant callers with subsequent
SciClone [4] tumor heterogeneity analysis. For comparison, we evalu-
ated corresponding serial tumor sections of hematoxylin and eosin
(H&E) and immunohistochemistry (IHC) digitized images for TP. A
subset of H&E slides were read by pathologists, while scanned IHC
images were read by deep-learning algorithms on the PathAI plat-
form (Boston, MA) for each tumor type, to distinguish cancer cells
from immune and other non-cancerous cell types based on
morphology.
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